Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
Strong Start to 2024 with Significant Revenue Growth and Strategic Financial Management
Significant Growth in Q1 2024 Spurs Optimism Amid Strategic Acquisitions